© 2018 OCNI

Kate Attfield PhD Senior Postdoctoral Fellow

Kate completed her B.Sc. in Molecular Genetics at Sussex University in 2004, and then studied for her Ph.D in Cancer Immunology in Southampton, under the supervision of Prof. Aymen Al-Shamkhani. Kate joined Prof. Lars Fugger’s lab in 2008 as a postdoc and has gained expertise in working with several humanised EAE models. Kate has an extensive background in cellular immunology and currently studies the role of MS susceptibility variants, with specific focus on those related to the immune system. Kate is now a senior postdoc within the lab and is actively involved in several collaborative projects within and outside of the group.

 

Publications 

Invited publications:

Attfield, KE., Dendrou, CA., Fugger, L. (2012) Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis. Immunol Rev. 1, 10-22

 

Attfield, KE., Fugger, L. (2013) TCR transgenic mice that shed light on immune and environmental regulators in multiple sclerosis. J Immunol. 190, 3015-7

 

Publications:

Kaur GGras SMobbs JIVivian JPCortes ABarber TKuttikkatte SBJensen LTAttfield KEDendrou CACarrington MMcVean GPurcell AWRossjohn JFugger L. Structural and regulatory diversity shape HLA-C protein expression levels. (2017) Nature Communications

Dendou, CA., Cortes A., Shipman, L., Evans, HG., Attfield, KE., Jostins, L., Barber, T., Kaur, G., Kuttikkatte, SB., Leach, OA., Desel, C., Faergeman, SL., Cheeseman, J., Neville, MJ., Sawcer, S., Compston, A., Johnson, AR., Everett, C., Bell, JI., Karpe, F., Ultsch, M., Eigenbrot, C., McVean G., Fugger, L. (2016) Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. Nov 2;8(363):363ra149

 

Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K. (2016). Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor.

Neurol Neuroimmunol Neuroinflamm. May 17;3(4):e241.

 

Moutsianas, L., Jostins, L., Beecham, A.H., Dilthey, A.T., Xifara, D.K., Ban, M., Shah, T.S., Patsopoulos, N.A., Alfredsson, L., Anderson, C.A., Attfield, KE., Baranzini, S.E., Barrett, J., Binder, T.M., Booth, D., Buck, D., Celius, E.G., Cotsapas, C., D'Alfonso, S., Dendrou, C.A., Donnelly, P., Dubois, B., Fontaine, B., Fugger, L., Goris, A., Gourraud, P.A., Graetz, C., Hemmer, B., Hillert, J.; International IBD Genetics Consortium (IIBDGC), Kockum, I., Leslie, S., Lill, C.M., Martinelli-Boneschi, F., Oksenberg, J.R., Olsson, T., Oturai, A., Saarela, J., Søndergaard, H.B., Spurkland, A., Taylor, B., Winkelmann, J., Zipp, F., Haines, J.L., Pericak-Vance, M.A., Spencer, C.C., Stewart, G., Hafler, D.A., Ivinson, A.J., Harbo, H.F., Hauser, S.L., De Jager, P.L., Compston, A., McCauley, J.L., Sawcer, S., McVean, G.; International Multiple Sclerosis Genetics Consortium. (2015) Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 47, 1107-13

 

Willing ALeach OAUfer FAttfield KESteinbach KKursawe NPiedavent MFriese MA. (2014) CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J Immunol. Oct;44(10):3119-28

 

Gregory, A. P., Dendrou, C. A., Attfield, KE., Haghikia, A., Xifara, D. K., Butter, F., Poschmann, G., Kaur, G., Lambert, L., Leach, O. A., Promel, S., Punwani, D., Felce, J. H., Davis, S. J., Gold, R., Nielsen, F. C., Siegel, R. M., Mann, M., Bell, J. I., McVean, G., Fugger, L. (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508-1